Top ▲

Peroxisome proliferator-activated receptor-γ

Click here for help

Immunopharmacology Ligand  Target has curated data in GtoImmuPdb

Target id: 595

Nomenclature: Peroxisome proliferator-activated receptor-γ

Systematic Nomenclature: NR1C3

Family: 1C. Peroxisome proliferator-activated receptors

Gene and Protein Information Click here for help
Species AA Chromosomal Location Gene Symbol Gene Name Reference
Human 505 3p25.2 PPARG peroxisome proliferator activated receptor gamma 3,42,107
Mouse 505 6 53.41 cM Pparg peroxisome proliferator activated receptor gamma 141
Rat 505 4q42 Pparg peroxisome proliferator-activated receptor gamma 44
Previous and Unofficial Names Click here for help
PPARG1 | PPARG2 | PPARgamma | nuclear receptor subfamily 1 group C member 3 | PPARgamma2
Database Links Click here for help
Alphafold
CATH/Gene3D
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Orphanet
Pharos
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Peroxisome proliferator-activated receptor-γ (ligand binding domain)
PDB Id:  1NYX
Ligand:  ragaglitazar
Resolution:  2.65Å
Species:  Human
References:  32
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of PPARgamma in complex with compound (R)-16
PDB Id:  6Y3U
Ligand:  (R)-16 [PMID: 32267688]
Resolution:  2.62Å
Species:  Human
References:  46
Natural/Endogenous Ligands Click here for help
15-deoxy-Δ-12,14-prostaglandin J2
linoleic acid
Comments: Fatty acids, prostaglandin J2 and eisosanoids are reported natural ligands

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
farglitazar Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Partial agonist 7.5 pKd 50,135
pKd 7.5 [50,135]
rosiglitazone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Full agonist 7.4 pKd 50,74,134
pKd 7.4 [50,74,134]
indomethacin Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Partial agonist 7.4 pKd 37,74
pKd 7.4 [37,74]
[125I]SB-236636 Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Full agonist 7.1 pKd 134
pKd 7.1 [134]
GW2331 Small molecule or natural product Ligand has a PDB structure ? Full agonist 6.5 pKd 62
pKd 6.5 [62]
[3H]GW2331 Small molecule or natural product Ligand is labelled Ligand is radioactive ? Full agonist 6.5 pKd 62
pKd 6.5 [62]
MK-0767 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.5 pKd 87-88
pKd 6.5 [87-88]
PAT5A Small molecule or natural product Hs Partial agonist 6.3 pKd 83,125
pKd 6.3 [83,125]
netoglitazone Small molecule or natural product Hs Full agonist 6.3 pKd 102
pKd 6.3 [102]
linoleic acid Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Hs Full agonist 5.3 pKd 37,135
pKd 5.3 [37,135]
BADGE Small molecule or natural product Hs Full agonist 4.0 pKd 9,129
pKd 4.0 [9,129]
GW1929 Small molecule or natural product Ligand has a PDB structure Hs Full agonist 8.8 pKi 12
pKi 8.8 [12]
L-796449 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 8.7 pKi 7
pKi 8.7 [7]
GW7845 Small molecule or natural product Hs Full agonist 8.4 pKi 22,50
pKi 8.4 [22,50]
bardoxolone Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Partial agonist 8.0 pKi 127
pKi 8.0 [127]
L-783483 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist 7.8 pKi 7
pKi 7.8 [7]
L-165461 Small molecule or natural product Hs Full agonist 7.8 pKi 7
pKi 7.8 [7]
AD5075 Small molecule or natural product Hs Full agonist 7.7 pKi 7-8
pKi 7.7 [7-8]
[3H]AD5075 Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Full agonist 7.7 pKi 6
pKi 7.7 [6]
rosiglitazone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Agonist 6.9 pKi 79
pKi 6.9 (Ki 1.2x10-7 M) [79]
FMOC-L-Leucine Small molecule or natural product Hs Partial agonist 6.0 pKi 104
pKi 6.0 [104]
troglitazone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Full agonist 5.8 pKi 6
pKi 5.8 (Ki 1.585x10-6 M) [6]
GW409544 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist 9.6 pEC50 49,130
pEC50 9.6 [49,130]
(R)-16 [PMID: 32267688] Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 8.8 pEC50 46
pEC50 8.8 (EC50 1.6x10-9 M) [46]
Description: Measuring nuclear receptor modulation in Gal4-hybrid reporter gene assays conducted in transiently transfected HEK293T cells.
edaglitazone Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 7.4 pEC50 30
pEC50 7.4 (EC50 3.56x10-8 M) [30]
Description: Measuring agonist-induced cofactor recruitment.
elafibranor Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 7.3 pEC50 108
pEC50 7.3 (EC50 4.7x10-8 M) [108]
reglitazar Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.1 pEC50 118
pEC50 7.1 [118]
chiglitazar Small molecule or natural product Approved drug Click here for species-specific activity table Hs Agonist 7.1 pEC50 77
pEC50 7.1 (EC50 8x10-8 M) [77]
Description: Measuring transactivation by human PPARδ in U-2OS cells
MK-0767 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.0 pEC50 31
pEC50 7.0 [31]
lanifibranor Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 6.7 pEC50 10
pEC50 6.7 (EC50 2.06x10-7 M) [10]
MDG 548 Small molecule or natural product Immunopharmacology Ligand Hs Agonist 6.7 pEC50 89
pEC50 6.7 (EC50 2.15x10-7 M) [89]
Description: Measured by TR-FRET analysis.
triple modulator 10 [PMID: 29878767] Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Partial agonist 6.5 pEC50 113
pEC50 6.5 (EC50 3x10-7 M) [113]
GW9578 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.0 pEC50 13
pEC50 6.0 [13]
seladelpar Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Agonist <6.0 pEC50 139
pEC50 <6.0 (EC50 >1x10-6 M) [139]
Description: Agonist activity determined by cell based transactivation assay.
zafirlukast Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 5.6 pEC50 113
pEC50 5.6 (EC50 2.44x10-6 M) [113]
ciglitazone Small molecule or natural product Hs Full agonist 4.6 pEC50 50
pEC50 4.6 [50]
MRL24 Small molecule or natural product Ligand has a PDB structure Hs Partial agonist 9.0 pIC50 1
pIC50 9.0 (IC50 1x10-9 M) In vitro hPPARγ binding [1]
MRL20 Small molecule or natural product Ligand has a PDB structure Hs Partial agonist 8.7 pIC50 1
pIC50 8.7 (IC50 2x10-9 M) In vitro hPPARγ binding [1]
SB-219994 Small molecule or natural product Hs Full agonist 8.7 pIC50 134
pIC50 8.7 [134]
LY-510929 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 8.0 pIC50 131,146
pIC50 8.0 [131,146]
AD-5061 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.7 pIC50 109-110
pIC50 7.7 [109-110]
TZD18 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.2 pIC50 45
pIC50 7.2 [45]
L-764406 Small molecule or natural product Hs Partial agonist 7.2 pIC50 34
pIC50 7.2 [34]
ragaglitazar Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist 7.0 pIC50 20,32,97
pIC50 7.0 [20,32,97]
GW0072 Small molecule or natural product Ligand has a PDB structure Hs Partial agonist 7.0 pIC50 95
pIC50 7.0 [95]
nTzDpa Small molecule or natural product Ligand has a PDB structure Hs Partial agonist 6.5 pIC50 8
pIC50 6.5 [8]
15-deoxy-Δ-12,14-prostaglandin J2 Small molecule or natural product Ligand is endogenous in the given species Hs Full agonist 6.3 pIC50 61-62,90,93,119
pIC50 6.3 [61-62,90,93,119]
troglitazone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Full agonist 6.3 pIC50 50,134
pIC50 6.3 (IC50 5.012x10-7 M) [50,134]
LY-465608 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.3 pIC50 11
pIC50 6.3 [11]
pioglitazone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Full agonist 6.2 pIC50 50,110,134
pIC50 6.2 [50,110,134]
SB-219993 Small molecule or natural product Hs Full agonist 5.5 pIC50 134
pIC50 5.5 [134]
VCE-004.3 Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 5.5 pIC50 27
pIC50 5.5 (IC50 3.5x10-6 M) [27]
tirotundin Small molecule or natural product Hs Agonist 4.6 pIC50 78
pIC50 4.6 (IC50 2.7x10-5 M) [78]
Description: Measuring PPARγ transactivation in response to compound binding directly to the receptor's ligand binding domain.
tagitinin A Small molecule or natural product Hs Agonist 4.3 pIC50 78
pIC50 4.3 (IC50 5.5x10-5 M) [78]
Description: Measuring PPARγ transactivation in response to compound binding directly to the receptor's ligand binding domain.
mesalazine Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Full agonist 1.8 pIC50 106
pIC50 1.8 [106]
DRF 2519 Small molecule or natural product ? Full agonist - - 19
[19]
ibuprofen Small molecule or natural product Approved drug Immunopharmacology Ligand ? Full agonist - - 57,65
[57,65]
diclofenac Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand ? Partial agonist - - 65
[65]
COOH Small molecule or natural product ? Full agonist - - 15,68
[15,68]
LG100754 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist - - 17,38
[17,38]
View species-specific agonist tables
Agonist Comments
Various endogenous fatty acid agonists , with pIC50 values of approximately 6, have been reported [130].
VCE-004.3 does not activate PPARα- or PPARδ-mediated transcription [27].
Antagonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
resveratrol Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Antagonist 5.8 pKd 14
pKd 5.8 (Kd 1.4x10-6 M) [14]
T0070907 Small molecule or natural product Ligand has a PDB structure Hs Antagonist 9.0 pKi 71
pKi 9.0 (Ki 1x10-9 M) [71]
CDDO-Me Small molecule or natural product Hs Antagonist 6.9 pKi 127
pKi 6.9 (Ki 1.3x10-7 M) [127]
diclofenac Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Antagonist 6.2 pKi 2
pKi 6.2 [2]
BADGE Small molecule or natural product Hs Antagonist 4.0 pKi 129
pKi 4.0 [129]
GW9662 Small molecule or natural product Ligand has a PDB structure Hs Irreversible inhibition 8.1 pIC50 73
pIC50 8.1 [73]
bexarotene Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist ~5.5 pIC50 80
pIC50 ~5.5 (IC50 ~3x10-6 M) [80]
Description: Measured using a TR-FRET competitive displacement assay.
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound 10 [O'Mahony et al., 2022] Small molecule or natural product Ligand has a PDB structure Hs Binding 7.6 pIC50 94
pIC50 7.6 (IC50 2.4x10-8 M) [94]
Description: PPARγ binding
Immunopharmacology Comments
PPARγ agonists have anti-inflammatory effects. Full PPARγ agonists can cause undesireable weight gain, but partial agonists are devoid of this adverse effect and retain the anti-inflammatory effects of PPARγ modulation.
The PPARγ agonist MDG 548 boosts the inflammatory phenotype of microglia and enhances their phagocytic capacity [69]. These actions are proposed to mediate the compound's neuroprotective effect.
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process:  Immune regulation
Immuno Process:  Immune system development
Immuno Process:  Cytokine production & signalling
Immuno Process:  Antigen presentation
Immuno Process:  Cellular signalling
DNA Binding Click here for help
Structure:  Heterodimer, RXR partner
HRE core sequence:  5'-AACTAGGNCA A AGGTCA-3'
Response element:  DR1
Co-binding Partners Click here for help
Name Interaction Effect Reference
RXR Physical, Functional DNA binding 63
Main Co-regulators Click here for help
Name Activity Specific Ligand dependent AF-2 dependent Comments References
WWTR1 Co-repressor No Yes No 52
SCAND1 Co-activator Yes Yes Yes 16
NCOA4 Co-activator Yes No No 48
PPARGC1A Co-activator No Yes Yes 53-54,64,96,98
PPARGC1B Co-activator No Yes Yes 43,58,64,96,98
CREBBP Co-activator No Yes Yes 84,140
EP300 Co-activator No Yes Yes 41
CITED2 Co-activator No Yes Yes 120
NCOR2 Co-repressor Yes No No 56,136
NCOA7 Co-activator No No No 117
NCOA6 Co-activator No Yes Yes 100,142
PRMT2 Co-activator No Yes No 99
TGS1 Co-activator No Yes No 143
NCOA1 Co-activator No No No 101,140,143
NCOA2 Co-activator No Yes Yes 72
NCOA3 Co-activator No No Yes 85
NRIP1 Co-repressor No Yes Yes 123
SMARCA1 Co-activator No No No 25,76
SAFB Co-repressor Yes No No 24
NCOR1 Co-repressor No No No 29,136,138
MED1 Co-activator No Yes Yes 133,144
Main Target Genes Click here for help
Name Species Effect Technique Comments References
Apoa2: apolipoprotein A-II Mouse Activated EMSA, ChIP 126
Fabp4: fatty acid binding protein 4 Mouse Activated ChIP 121
Pck1: phosphoenolpyruvate carboxykinase 1 Mouse Activated Transient transfection, EMSA 122
Ucp1: uncoupling protein 1 Mouse Activated Transient transfection 116,132
Acsf2: acyl CoA-synthetase Mouse Activated EMSA, Other 82,115
Lpl: lipoprotein lipase Mouse Activated EMSA 114
Slc27a: solute carrier family 27 member 1 Mouse Activated Transient transfection, EMSA 40
Tissue Distribution Click here for help
Adipose tissues, lymphoid tissues, colon, liver and heart
Species:  Human
Technique:  Northern Blot, Western Blot, Immunohistochemistry
References:  29
Tissue Distribution Comments
Expression of Ppar-γ in mice and rats has been detected in adipose, lymphoid tissues and the colon.
Functional Assays Click here for help
BADGE: adipogenesis assay
Species:  Mouse
Tissue:  3T3-L1, 3T3-F442A cells
Response measured:  staining of lipids with oil Red O, adipocyte-specific markers
References:  129
Induction of apoptotic cell death
Species:  Rat
Tissue:  C6 glioma cells
Response measured:  lipogenesis by TUNEL staining
References:  43
Adipocyte differentiation assay
Species:  Human
Tissue:  C3H10T1/2 cells
Response measured:  triglyceride accumulation in adipocytes by adding lipoprotein lipase and glycerol phosphatase oxidase
References:  12,75
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg
MGI:97747  MP:0004185 abnormal adipocyte glucose uptake PMID: 19117549 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6
MGI:97747  MP:0000013 abnormal adipose tissue distribution PMID: 15254591 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:97747  MP:0000013 abnormal adipose tissue distribution PMID: 17003330 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified
MGI:97747  MP:0000013 abnormal adipose tissue distribution PMID: 15919792 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ
MGI:97747  MP:0000003 abnormal adipose tissue morphology PMID: 15716267 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6
MGI:2450254  MGI:97747  MP:0005666 abnormal adipose tissue physiology PMID: 15070754 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR
MGI:97747  MP:0002459 abnormal B cell physiology PMID: 10549291 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0001993 abnormal blinking PMID: 16845470 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)
MGI:97747  MP:0001777 abnormal body temperature regulation PMID: 14603033 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0000168 abnormal bone marrow development PMID: 15067317 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0002397 abnormal bone marrow morphology PMID: 15067317 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0008271 abnormal bone ossification PMID: 15067317 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg
MGI:97747  MP:0003795 abnormal bone structure PMID: 19117549 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6
MGI:2450253  MGI:97747  MP:0002971 abnormal brown adipose tissue morphology PMID: 14660788 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0002971 abnormal brown adipose tissue morphology PMID: 15249658 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
MGI:97747  MP:0002971 abnormal brown adipose tissue morphology PMID: 17921248 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
MGI:97747  MP:0002971 abnormal brown adipose tissue morphology PMID: 17921248 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6
MGI:2450254  MGI:97747  MP:0009116 abnormal brown fat cell morphology PMID: 15070754 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ
MGI:97747  MP:0009116 abnormal brown fat cell morphology PMID: 15716267 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
MGI:97747  MP:0009116 abnormal brown fat cell morphology PMID: 17921248 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6
MGI:2450253  MGI:97747  MP:0009135 abnormal brown fat cell size PMID: 14660788 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0000130 abnormal cancellous bone morphology PMID: 15067317 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA
MGI:97747  MP:0005076 abnormal cell differentiation PMID: 10549291  15067317 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0005076 abnormal cell differentiation PMID: 10549291 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg
MGI:97747  MP:0005076 abnormal cell differentiation PMID: 19117549 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae
MGI:97747  MP:0004560 abnormal chorionic plate morphology PMID: 10549290 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)
MGI:97747  MP:0001573 abnormal circulating alanine transaminase level PMID: 14603033 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6
MGI:97747  MP:0009165 abnormal endocrine pancreas morphology PMID: 15254591 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6
MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 15254591 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 17003330 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 17465682 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6
MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 14536066 
Dok1tm1Yyam|Ppargtm1Laz Dok1tm1Yyam/Dok1tm1Yyam,Ppargtm1Laz/Ppargtm1Laz
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6
MGI:893587  MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 18204460 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 10549291  15067317 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae
MGI:97747  MP:0008788 abnormal fetal cardiomyocyte morphology PMID: 10549290 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0001406 abnormal gait PMID: 16845470 
Pparg+|Ppargtm1Rev Ppargtm1Rev/Pparg+
involves: 129S4/SvJae * C57BL/6J
MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 10675354 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)
MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 14603033 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:104663  MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 17003330 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified
MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 15919792 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 17465682 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6
MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 14536066 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6
MGI:97747  MP:0005335 abnormal gonadal fat pad morphology PMID: 15254591 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:104663  MGI:97747  MP:0005335 abnormal gonadal fat pad morphology PMID: 17003330 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA
MGI:97747  MP:0000267 abnormal heart development PMID: 10549291 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
MGI:97747  MP:0000607 abnormal hepatocyte morphology PMID: 17921248 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR
MGI:97747  MP:0001800 abnormal humoral immune response PMID: 10549291 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6
MGI:97747  MP:0005336 abnormal inguinal fat pad morphology PMID: 15254591 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0003564 abnormal insulin secretion PMID: 17465682 
Ppargtm1.2Mtz|Tg(Krt1-10-cre)1Pcn Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Krt1-10-cre)1Pcn/0
involves: C57BL/6 * SJL
MGI:3629071  MGI:97747  MP:0002655 abnormal keratinocyte morphology PMID: 16751185 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:97747  MP:0002118 abnormal lipid homeostasis PMID: 17003330 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0002118 abnormal lipid homeostasis PMID: 17465682 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0000598 abnormal liver morphology PMID: 17465682 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0001392 abnormal locomotor activity PMID: 17465682 
Ppargtm1.1Gonz|Tg(Mx1-cre)1Cgn Ppargtm1.1Gonz/Ppargtm1.1Gonz,Tg(Mx1-cre)1Cgn/?
involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N
MGI:2176072  MGI:97747  MP:0002451 abnormal macrophage physiology PMID: 11909955 
Ppargtm1Gonz|Tg(MMTV-cre)1Mam Ppargtm1Gonz/Ppargtm1Gonz,Tg(MMTV-cre)1Mam/?
involves: 129X1/SvJ * FVB
MGI:2176162  MGI:97747  MP:0006269 abnormal mammary gland growth during pregnancy PMID: 11884400 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0001516 abnormal motor coordination/ balance PMID: 16845470 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ
MGI:97747  MP:0004130 abnormal muscle cell glucose uptake PMID: 15716267 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae
MGI:97747  MP:0000278 abnormal myocardial fiber morphology PMID: 10549290 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae
MGI:97747  MP:0002189 abnormal myocardial trabeculae morphology PMID: 10549290 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0008395 abnormal osteoblast differentiation PMID: 15067317 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0005215 abnormal pancreatic islet morphology PMID: 17465682 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:97747  MP:0005215 abnormal pancreatic islet morphology PMID: 17465682 
Ppargtm1.1Mtz Ppargtm1.1Mtz/Ppargtm1.1Mtz
involves: C57BL/6
MGI:97747  MP:0001712 abnormal placenta development PMID: 15070754 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae
MGI:97747  MP:0001716 abnormal placenta labyrinth morphology PMID: 10549290 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA
MGI:97747  MP:0001716 abnormal placenta labyrinth morphology PMID: 10549291 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae
MGI:97747  MP:0008803 abnormal placental labyrinth vasculature morphology PMID: 10549290 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA
MGI:97747  MP:0008803 abnormal placental labyrinth vasculature morphology PMID: 10549291 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae
MGI:97747  MP:0001711 abnormal placenta morphology PMID: 10549290 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0003088 abnormal prepulse inhibition PMID: 16845470 
Atp2b2+|Atp2b2m1Mae|Pparg+|Ppargtm2Mae Atp2b2m1Mae/Atp2b2+,Ppargtm2Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0003088 abnormal prepulse inhibition PMID: 16845470 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0001961 abnormal reflex PMID: 16845470 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0005164 abnormal response to injury PMID: 11889020 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR
MGI:97747  MP:0005164 abnormal response to injury PMID: 11159886 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0002792 abnormal retinal vasculature morphology PMID: 17003451 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:104663  MGI:97747  MP:0000759 abnormal skeletal muscle morphology PMID: 17003330 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0000759 abnormal skeletal muscle morphology PMID: 17465682 
Ppargtm1.2Mtz|Tg(Krt1-10-cre)1Pcn Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Krt1-10-cre)1Pcn/0
involves: C57BL/6 * SJL
MGI:3629071  MGI:97747  MP:0002060 abnormal skin morphology PMID: 16751185 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:97747  MP:0000187 abnormal triglyceride level PMID: 17003330 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae
MGI:97747  MP:0005033 abnormal trophoblast giant cells PMID: 10549290 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae
MGI:97747  MP:0005031 abnormal trophoblast layer morphology PMID: 10549290 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0001490 abnormal vibrissae reflex PMID: 16845470 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0003491 abnormal voluntary movement PMID: 16845470 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6
MGI:2450253  MGI:97747  MP:0001781 abnormal white adipose tissue amount PMID: 14660788 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:104663  MGI:97747  MP:0001781 abnormal white adipose tissue amount PMID: 17003330 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0002970 abnormal white adipose tissue morphology PMID: 15249658 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ
MGI:97747  MP:0002970 abnormal white adipose tissue morphology PMID: 15716267 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
MGI:97747  MP:0002970 abnormal white adipose tissue morphology PMID: 17921248 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0005670 abnormal white adipose tissue physiology PMID: 15249658 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified
MGI:97747  MP:0005670 abnormal white adipose tissue physiology PMID: 15919792 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6
MGI:2450254  MGI:97747  MP:0009117 abnormal white fat cell morphology PMID: 15070754 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
MGI:97747  MP:0009117 abnormal white fat cell morphology PMID: 17921248 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
MGI:97747  MP:0009132 abnormal white fat cell size PMID: 17921248 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0006358 absent pinna reflex PMID: 16845470 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0006359 absent startle reflex PMID: 16845470 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
MGI:97747  MP:0008843 absent subcutaneous adipose tissue PMID: 17921248 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0001393 ataxia PMID: 16845470 
Ppargtm1.1Gonz|Tg(Myhca-cre)1Abel Ppargtm1.1Gonz/Ppargtm1.1Gonz,Tg(Myhca-cre)1Abel/0
involves: 129X1/SvJ * FVB
MGI:2182090  MGI:97747  MP:0001625 cardiac hypertrophy PMID: 16051889 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0004893 decreased adiponectin level PMID: 15249658 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ
MGI:97747  MP:0004893 decreased adiponectin level PMID: 15716267 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:97747  MP:0004893 decreased adiponectin level PMID: 17003330 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:104663  MGI:97747  MP:0004893 decreased adiponectin level PMID: 17003330 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified
MGI:97747  MP:0004893 decreased adiponectin level PMID: 15919792 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0004893 decreased adiponectin level PMID: 17465682 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:97747  MP:0004893 decreased adiponectin level PMID: 17465682 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg
MGI:97747  MP:0006086 decreased body mass index PMID: 19117549 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0001265 decreased body size PMID: 16845470 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)
MGI:97747  MP:0001262 decreased body weight PMID: 14603033 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0001262 decreased body weight PMID: 15249658 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ
MGI:97747  MP:0001262 decreased body weight PMID: 15716267 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:104663  MGI:97747  MP:0001262 decreased body weight PMID: 17003330 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg
MGI:97747  MP:0001262 decreased body weight PMID: 19117549 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)
MGI:97747  MP:0001780 decreased brown adipose tissue amount PMID: 14603033 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6
MGI:2450253  MGI:97747  MP:0001780 decreased brown adipose tissue amount PMID: 14660788 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6
MGI:2450254  MGI:97747  MP:0001780 decreased brown adipose tissue amount PMID: 15070754 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0001780 decreased brown adipose tissue amount PMID: 10549291 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0009125 decreased brown fat cell lipid droplet size PMID: 15249658 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6
MGI:2450253  MGI:97747  MP:0009128 decreased brown fat cell number PMID: 14660788 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0009137 decreased brown fat lipid droplet number PMID: 15249658 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg
MGI:97747  MP:0005179 decreased circulating cholesterol level PMID: 19117549 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6
MGI:97747  MP:0002702 decreased circulating free fatty acid level PMID: 14536066 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0002727 decreased circulating insulin level PMID: 17465682 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0002727 decreased circulating insulin level PMID: 10549291 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0005668 decreased circulating leptin level PMID: 15249658 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6
MGI:97747  MP:0005668 decreased circulating leptin level PMID: 14536066 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6
MGI:97747  MP:0002644 decreased circulating triglyceride level PMID: 14536066 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg
MGI:97747  MP:0002644 decreased circulating triglyceride level PMID: 19117549 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0003910 decreased eating behavior PMID: 10549291 
Ppargtm1Lja Ppargtm1Lja/Ppargtm1Lja
involves: 129S1/Sv * 129X1/SvJ
MGI:97747  MP:0001698 decreased embryo size PMID: 15716267 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6
MGI:2450254  MGI:97747  MP:0009289 decreased epididymal fat pad weight PMID: 15070754 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:104663  MGI:97747  MP:0009269 decreased fat cell size PMID: 17003330 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0009283 decreased gonadal fat pad weight PMID: 15249658 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
MGI:97747  MP:0009283 decreased gonadal fat pad weight PMID: 17921248 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
MGI:97747  MP:0009283 decreased gonadal fat pad weight PMID: 17921248 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0010053 decreased grip strength PMID: 16845470 
Ppargtm1.1Gonz|Tg(Myhca-cre)1Abel Ppargtm1.1Gonz/Ppargtm1.1Gonz,Tg(Myhca-cre)1Abel/0
involves: 129X1/SvJ * FVB
MGI:2182090  MGI:97747  MP:0005333 decreased heart rate PMID: 16051889 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0009293 decreased inguinal fat pad weight PMID: 15249658 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6
MGI:2450253  MGI:97747  MP:0009295 decreased interscapular fat pad weight PMID: 14660788 
Ppargtm1Gonz|Tg(MMTV-cre)1Mam Ppargtm1Gonz/Ppargtm1Gonz,Tg(MMTV-cre)1Mam/?
involves: 129X1/SvJ * FVB
MGI:2176162  MGI:97747  MP:0001935 decreased litter size PMID: 11884400 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0009356 decreased liver triglyceride level PMID: 17465682 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6
MGI:2450254  MGI:97747  MP:0005459 decreased percent body fat PMID: 15070754 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0010379 decreased respiratory quotient PMID: 17465682 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0009305 decreased retroperitoneal fat pad weight PMID: 15249658 
Atp2b2+|Atp2b2m1Mae|Pparg+|Ppargtm2Mae Atp2b2m1Mae/Atp2b2+,Ppargtm2Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6J
MGI:105368  MGI:97747  MP:0001489 decreased startle reflex PMID: 16845470 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
MGI:97747  MP:0008844 decreased subcutaneous adipose tissue amount PMID: 17921248 
Ppargtm1.1Unc Ppargtm1.1Unc/Ppargtm1.1Unc
involves: 129S6/SvEvTac * C57BL/6J
MGI:97747  MP:0002843 decreased systemic arterial blood pressure PMID: 19884495 
Pparg+|Ppargtm1.1Unc Ppargtm1.1Unc/Pparg+
involves: 129S6/SvEvTac * C57BL/6J
MGI:97747  MP:0002843 decreased systemic arterial blood pressure PMID: 19884495 
Pparg+|Ppargtm1Uls Ppargtm1Uls/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:97747  MP:0010025 decreased total body fat amount PMID: 15231871 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ
MGI:97747  MP:0010025 decreased total body fat amount PMID: 15716267 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
MGI:104663  MGI:97747  MP:0010025 decreased total body fat amount PMID: 17003330 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified
MGI:97747  MP:0010025 decreased total body fat amount PMID: 15919792 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
MGI:97747  MP:0010025 decreased total body fat amount PMID: 10549291 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg
MGI:97747  MP:0008907 decreased total fat pad weight PMID: 19117549 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
MGI:104663  MGI:97747  MP:0005318 decreased triglyceride level PMID: 17465682 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)
MGI:97747  MP:0001783 decreased white adipose tissue amount PMID: 14603033 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0001783 decreased white adipose tissue amount PMID: 15249658 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ
MGI:97747  MP:0001783 decreased white adipose tissue amount PMID: 15716267 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0009131 decreased white fat cell number PMID: 15249658 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
MGI:97747  MP:0009133 decreased white fat cell size